Entity

Time filter

Source Type

Guelma, Algeria

Dekaken A.,El Okbi Hospital | Gouri A.,Laboratory of Medical Biochemistry | Bentorki A.A.,El Okbi Hospital | Yakhlef A.,Ibn Zohr Hospital
Annales de Biologie Clinique | Year: 2014

Primary hyperparathyroidism is a common endocrine disorder, asymptomatic and diagnosed through a fortuitous hypercalcemia. Browntumors are exceptional but severe hyperparathyroidism bone complications.We report in this paper an original observation of hyperparathyroidism due to a parathyroid adenoma presenting as a brown tumor. A 28 year-old girl admitted for a bone tumor of the knee, the blood test shows hypercalcemia with hyperparathyroidism, bone biopsy revealed giant cell lesions characteristic of brown tumors. Source


Gouri A.,Laboratory of Medical Biochemistry | Dekaken A.,El Okbi Hospital | Bentorki A.A.,Laboratory of Medical Biochemistry | Touaref A.,Laboratory of Medical Biochemistry | And 2 more authors.
Clinical Laboratory | Year: 2014

Background: Elevated serum uric acid (SUA) was usually associated with an increased risk of cardiovascular events and mortality in the general population. However, there are few reports concerning the clinical impact and the pathogenic role of uric acid (UA) in hemodialysis (HD) patients. The aim of the study was to investigate the relationship between SUA and various cardiovascular (CV) risk factors in HD patients. Methods: This retrospective, observational cohort study includes 45 HD patients with a mean age of 51.26 ± 15.21 years. The differences of the CV risk factors between the patients according to their SUA levels were investigated. Results: Age, cardiovascular diseases (CVD), increased creatinine, fasting blood glucose (FBG), corrected calcium (cCa), phosphate (P), cCa x P product, and LDL cholesterol levels were associated with lower SUA levels, whereas a higher SUA level was associated with diabetes mellitus (DM), hypertension, and increased triglycerides level (p < 0.01). In multiple regression analysis, history of diabetes (β = 0.360, p < 0.05), reduced corrected serum calcium (cCa) (β = -1.456, p < 0.01), and phosphate (P) levels (β = -1.752, p < 0.01) were predictive of an increased SUA concentration. Conclusions: Despite what has been demonstrated in the general population and DM patients, a lower SUA level in HD patients was associated with higher cardiovascular risk factors and high co-morbidity burden. Moreover, higher SUA concentrations may be cardioprotective in dialysis patients. Source


Gouri A.,Laboratory of Medical Biochemistry | Dekaken A.,El Okbi Hospital | Bentorki A.A.,Laboratory of Medical Biochemistry | Touaref A.,Ibn Zohr Hospital | And 3 more authors.
Pakistan Journal of Biological Sciences | Year: 2013

Elevated Serum Uric Acid (SUA) was usually associated with an increased risk of cardiovascular events and mortality in general population. However, there are few reports concerning the clinical impact and the pathogenic role of Uric Acid (UA) in Hemodialysis (HD) patients. The aim of the study was to investigate the relationship between SUA and various Cardiovascular (CV) risk factors in HD patients. This retrospective; observational cohort study includes 45 HD patients with a mean age of 51.26±15.21 years. The differences of the CV risk factors between the patients according to their SUA levels were investigated. Age, Cardiovascular Diseases (CVD), increased creatinine, Fasting Blood Glucose (FBG), Corrected Calcium (cCa), Phosphate (P), cCa x P product and LDL cholesterol levels were associated with lower SUA levels, whereas higher SUA level was associated with Diabetes Mellitus (DM), hypertension and increased triglycerides level (p<0.01). In multiple regression analysis, history of diabetes (β = 0.360, p<0.05), reduced corrected serum calcium (cCa) (β = -1.456, p<0.01) and Phosphate (P) levels (β = -1.752, p<0.01) were predictive of an increased SUA concentration. Despite from what has been demonstrated in the general population and DM patients, a lower SUA level in HD patients was associated with higher cardiovascular risk factors and high co-morbidity burden. Moreover, higher SUA concentrations may be cardioprotective in dialysis patients. © 2013 Asian Network for Scientific Information. Source


Gouri A.,Laboratory of Medical Biochemistry | Yakhlef A.,IBN | Dekaken A.,El Okbi Hospital | Bentorki A.A.,Laboratory of Medical Biochemistry
Annales de Biologie Clinique | Year: 2012

The occurrence of myocardial infarction in myeloproliferative disease is mostly attributed to coronary thrombosis due to hyperviscosity and thrombocytosis. We report a 55-year-old man case with polycythemia vera none diagnosed before and revealing with ST-segment elevation myocardial infarction; this is a relative rare association. The clinical status, comorbidities and patient outcome were studied. This case illustrates the importance of early diagnosis of polycythemia vera and research almost systemic thrombotic complications. Source


Gouri A.,Laboratory of Medical Biochemistry | Dekaken A.,El Okbi Hospital | Yakhlef A.,Ibn Zohr Hospital | Bentorki A.A.,Laboratory of Medical Biochemistry | Kouicem N.,Ibn Zohr Hospital
Immuno-Analyse et Biologie Specialisee | Year: 2012

Dyslipidemia is often observed in hemodialysis patients (HD), resulting in abnormal concentrations and composition of plasma lipoproteins. Non-high-density-lipoprotein cholesterol (Non HDL-C) has been proposed as a good estimator of the atherogenic potential in general population; however, there are limited data of non-HDL-C in hemodialysis patients. The objective of this study was to assess the prevalence of lipid abnormalities in a cohort of Algerian hemodialysis patients and to test the ability of non-HDL-C to identify non-traditional lipoprotein subclass risk factors in this population. Forty-five hemodialysis patients with a mean age of 51.26 ± 15.21 years participated in this study. The most frequent lipid alteration recorded was decreased HDL-C (75.5%), followed by increased non-HDL-C (73.4%) and hypertriglyceridemia (24.5%). The levels of total cholesterol, LDL-C and the LDL-C/HDL-C ratio were significantly higher and the HDL-C levels were significantly lower in the high non-HDL-C group than those in the low non-HDL-C group. Furthermore, a significant correlation was found between non-HDL-C and LDL-C levels (r=0.84, P<0.001), total cholesterol levels (r=0.75, P<0.001) and atherogenic index (r=0.62, P<0.001) in this population. Our study suggests that non-HDL-C may be the best lipoprotein parameter for managing dyslipidemia and evaluating cardiovascular disease risk among HD patients. © 2012 Elsevier Masson SAS. Source

Discover hidden collaborations